Clinical trial
Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma
NCT00369681 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other · Completed
Key facts
| NCT number | NCT00369681 |
|---|---|
| Title | Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma |
| Official title | Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin's Lymphoma |
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | Bleomycin, Rituximab, Dacarbazine, Doxorubicin, Vinblastine |
| Enrollment | 51 |
| Start date | May 1, 2006 |
| Primary completion | Oct 1, 2014 |
| Completion | Oct 1, 2014 |
| First posted | Aug 29, 2006 |
| Last update posted | Aug 27, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: